Daré Bioscience (NASDAQ:DARE) Prepares to Share Corporate Presentation on January 13, 2025

Daré Bioscience, Inc. recently announced that it intends to present a corporate presentation on January 13, 2025. The presentation, which will be made available on the company’s website in the “Investors” section, is aimed at various meetings with securities market participants and others.

Exhibit 99.1 attached to the Form 8-K filing is a copy of the corporate presentation scheduled for January 13, which the company plans to utilize in its upcoming engagements. The presentation will be accessible on the website under the “Presentations, Events & Webcasts” section.

It’s important to note that the information within this presentation is being furnished and should not be considered as a filed document under the Securities Exchange Act of 1934. While the presentation can be accessed through the website, it is not incorporated by reference into any filings under the Exchange Act or the Securities Act of 1933 without explicit mention.

Daré Bioscience, Inc. listed its address as 3655 Nobel Drive, Suite 260, San Diego, CA 92122, and provided a telephone number of (858) 926-7655 for investor inquiries.

Investors and stakeholders are encouraged to review the corporate presentation on January 13, 2025, for key insights into Daré Bioscience’s current and future endeavors.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Daré Bioscience’s 8K filing here.

Daré Bioscience Company Profile

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.